Welcome to our dedicated page for Cardiff Lexingto SEC filings (Ticker: CDIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiff Lexington Corporation filings document the public-company record for a Nevada healthcare services holding company whose operating platform is Nova Ortho and Spine. Securities Act registration statements and amendments cover a proposed common-stock offering, financial statements for the orthopedic, spine and pain-management clinic business, and related capital-structure disclosures.
Current reports on Form 8-K record material events including changes to the rights of Series N Senior Convertible Preferred Stock and board-level governance changes. The filings also identify the company's OTC-traded common stock context and disclose security-holder rights, offering documents and corporate actions tied to its healthcare-services strategy.
Cardiff Lexington Corporation reported a larger loss for the three months ended March 31, 2026 while relying heavily on debt financing. Revenue was $2,222,280, down from $2,915,567 a year earlier, reducing gross profit to $1,318,055. Operating results swung to a loss of $511,159, primarily due to $664,196 of share-based compensation and ongoing selling, general and administrative costs.
The bottom line was driven by $1,910,737 of interest expense and a $668,821 loss on derivative liabilities, producing a net loss of $3,092,074 and a basic and diluted loss per share of $0.23. Operating cash use was modest at $16,730, but the company raised $381,702 from financing, including $845,000 of new convertible notes.
At March 31, 2026, Cardiff held $683,507 in cash and $22,890,899 of accounts receivable tied to lien-based medical services, funded in part by an $18,922,173 line of credit under a $23,000,000 facility and $1,095,000 of convertible notes. Total liabilities were $24,630,858 against stockholders’ equity of $3,876,456 and an accumulated deficit of $82,855,513. Management disclosed substantial doubt about the company’s ability to continue as a going concern without additional capital.
Staley Louis Jack Sr. reported acquisition or exercise transactions in this Form 4 filing.
Cardiff Lexington Corp director Staley Louis Jack Sr. received a grant of 5,000 shares of Common Stock as a restricted stock award on April 1, 2026. The award was granted at a price of $0.00 per share as equity compensation, not an open-market purchase. The shares are scheduled to vest in equal installments quarterly over four quarters starting July 1, 2026, contingent on his continued service under the company’s 2024 Equity Incentive Plan. Following this grant, he beneficially owns 11,668 shares of Common Stock directly.
Pennington Catherine B. reported acquisition or exercise transactions in this Form 4 filing.
Cardiff Lexington Corp director Catherine B. Pennington received a grant of 5,000 shares of Common Stock as a restricted stock award under the company’s 2024 Equity Incentive Plan. The award vests quarterly over four quarters starting on July 1, 2026, subject to her Continuous Service.
Following this compensation-related grant, Pennington holds a total of 11,668 shares of Cardiff Lexington common stock directly. The grant was recorded at a price of $0.0000 per share, reflecting an equity award rather than an open-market purchase.
Johnson Gillard B. III reported acquisition or exercise transactions in this Form 4 filing.
Cardiff Lexington Corp director Johnson Gillard B. III received a grant of 5,000 shares of Common Stock as a restricted stock award under the company’s 2024 Equity Incentive Plan. These shares will vest in four quarterly installments starting on July 1, 2026, contingent on his continued service. Following this compensation-related award, he directly holds 11,668 shares of Common Stock.
Cardiff Lexington Corporation is offering 1,739,130 shares of common stock based on an assumed public offering price of $3.45 per share. The prospectus states net proceeds are expected to be approximately $4.9 million, or $5.7 million if the underwriters exercise the full over-allotment option.
The offering is contingent on the company’s application to list its common stock on Nasdaq. The company implemented a 1-for-3 reverse stock split on January 12, 2026, and financials for the year ended December 31, 2025 are included; revenue was $11,535,577 and net loss was $(5,507,592).
Cardiff Lexington Corporation files its annual report describing a healthcare-focused holding company with all current revenue from Nova Ortho and Spine clinics in Florida and Georgia and a small, non‑operating real estate subsidiary, Edge View Properties.
The company’s auditor includes a going concern warning, citing an accumulated deficit of $79,490,980 and negative operating cash flow of $2,853,274 for the year ended December 31, 2025. Management estimates its eleven clinics are running at about 35% capacity, with 270–375 patients per month, and is pursuing organic growth and acquisitions.
The model relies on plaintiff-related orthopedic care with accounts receivable typically collected over 12–24 months, leading to liquidity strain and dependence on external financing. Management believes it may need $5–10 million of additional capital to execute its acquisition strategy.
Cardiff Lexington Corporation amended the terms of its Series N Senior Convertible Preferred Stock. The company filed a Certificate of Amendment in Nevada that eliminates the prior redemption provisions, which had allowed the company to optionally redeem the shares and had given holders a mandatory redemption right in certain situations.
The change was approved by the required holders of the Series N preferred shares, meaning the investor group in that class consented to removing these redemption features. The amendment is attached as an exhibit, providing the full, updated terms of the Series N Senior Convertible Preferred Stock.
Cardiff Lexington Corp’s chief executive officer and director Alex H. Cunningham converted a large deferred pay balance into equity. On January 29, 2026, deferred compensation of $2,365,242 owed to him by the company was cancelled in exchange for 556,528 shares of common stock at $0 per share.
After this transaction, Cunningham directly beneficially owned 3,914,230 shares of common stock, and an additional 889,398 shares were held indirectly through the Alexander Hunt Cunningham, Sr. Revocable Trust.
Cardiff Lexington Corporation filed Amendment No. 2 to its S-1 registration statement. The company states this amendment is being made solely to file additional and updated exhibits listed in Item 16, such as a form of underwriting agreement, various preferred stock designations, warrant forms, loan and security agreements, employment and equity incentive plan documents, and legal opinions related to the shares and representative’s warrant. The preliminary prospectus in Part I and the remainder of Part II of the original registration statement remain unchanged and are omitted from this amendment. The filing also restates standard undertakings regarding indemnification under the Securities Act and is signed on behalf of the company by Chief Executive Officer and Chairman Alex Cunningham and other officers and directors.